2.1
Avapritinib (Ayvakyt) is indicated 'as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated haematological neoplasm (SM-AHN), or mast cell leukaemia (MCL)'.
2 Information about avapritinib
Marketing authorisation
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for avapritinib.
Price
2.3
The list price for avapritinib is £26,667 for a 30‑pack of 25‑mg, 50‑mg, 100‑mg or 200‑mg tablets (excluding VAT; company submission).
2.4
The company has a commercial arrangement. This makes avapritinib available to the NHS with a discount. The size of the discount is commercial in confidence.